Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07700056 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 5 → 13 locations Eligibility criteria expanded, about 15 words · Secondary endpoints: details revised at 4 of 5 entries · Study description expanded, about 4 words Show 3 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Study description expanded, about 4 words
  2. Recruitment opened Trial sites expanded: 0 → 5 locations · Start date changed from estimate of Aug 14, 2026 to Aug 24, 2026v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 5 locations
    • Start date changed from estimate of Aug 14, 2026 to Aug 24, 2026
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
Trial Details
NCT Number NCT07700056
Lead Sponsor Novartis Pharmaceuticals
Conditions Chronic Pruritus of Unknown Origin
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov